A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Part of paid clinical trials in Chandler, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT06109311
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally.
  • Placebo — DRUG
    Administered orally.

Study Details

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.

Key Dates

Start date
Nov 10, 2023
Status verified
Oct 2025
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025

Study Design

Enrollment
546 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron Dose 1
    Participants will receive orforglipron orally.
  • Experimental: Orforglipron Dose 2
    Participants will receive orforglipron orally.
  • Experimental: Orforglipron Dose 3
    Participants will receive orforglipron orally.
  • Placebo Comparator: Placebo
    Participants will receive placebo orally.

Primary Outcome Measure

Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40 ]

Locations (25)

FacilityCityStateZIPSite coordinators
MD First Research - ChandlerChandlerArizona85286-
Phoenix Clinical LLCPhoenixArizona85014-
SanRo Clinical Research GroupBryantArkansas72022-
Velocity Clinical Research, GardenaGardenaCalifornia90247-
Loma Linda University Health SystemLoma LindaCalifornia92350-
Western University of Health SciencesPomonaCalifornia91766-
Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.Toluca LakeCalifornia91602-
CMR of Greater New Haven, LLCHamdenConnecticut06517-
Care Access - BrandonBrandonFlorida33510-
Encore Medical ResearchHollywoodFlorida33024-
Encore Medical Research - WestonWestonFlorida33331-
Orita Clinical ResearchDecaturGeorgia30034-
Bingham Memorial HospitalBlackfootIdaho83221-
St. Luke's Humphreys Diabetes Center: BoiseBoiseIdaho83702-
Cotton O'Neil Diabetes & EndocrinologyTopekaKansas66606-
The Research Group of LexingtonLexingtonKentucky40503-
Clinvest Headlands LlcSpringfieldMissouri65807-
Richmond University Medical CenterStaten IslandNew York10310-
Velocity Clinical Research, Mt. AuburnCincinnatiOhio45219-
Velocity Clinical Research, MedfordMedfordOregon97504-
Tristar Clinical InvestigationsPhiladelphiaPennsylvania19114-
Frontier Clinical Research, LLCScottdalePennsylvania15683-
Lifedoc Research - Lenox Park DriveMemphisTennessee38115-
Consano Clinical Research, LLCShavano ParkTexas78231-
Texas Valley Clinical ResearchWeslacoTexas78596-

Related coverage on Hipa.ai

Find similar trials in Chandler, AZ

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
MD First Research - Chandler· Chandler, AZPhoenix Clinical LLC· Phoenix, AZSanRo Clinical Research Group· Bryant, ARVelocity Clinical Research, Gardena· Gardena, CALoma Linda University Health System· Loma Linda, CAWestern University of Health Sciences· Pomona, CA

Related Studies